Clinical trial sees rectal cancer in remission for all participants – The Jerusalem Post

A small clinical trial in New York City sent rectal cancer into remission for every patient that was involved by using a unique immunotherapeutic treatment.

The trial, which was later published as a paper on Sunday in the New England Journal of Medicine, gave all the patients involved the immunotherapy treatment “Dostarlimab” – which then stunned doctors as it returned a 100% success rate for all patients in clinical trials. The immunotherapy had shrunk the tumors the patients had much quicker than the medical professionals were expecting.

 

Source: Clinical trial sees rectal cancer in remission for all participants – The Jerusalem Post

3 thoughts on “Clinical trial sees rectal cancer in remission for all participants – The Jerusalem Post”

Comments are closed.